Facebook
Twitter
LinkedIn
ForwardIncorporating Personalized Patient Management Strategies into the Treatment of Multiple Sclerosis
This activity will review recent advances in treatment options for patients with multiple sclerosis. Expert faculty will discuss the mechanism of MS in terms of the clinical and pathological worsening of the disease. The diagnosis of MS will be broken down into clinical subtypes, with emphasis on the new disease courses. The safety and efficacy and emerging therapeutic options will be analyzed and clinical trials will be discussed. The faculty will provide insight to physicians on how to personalize MS treatment for their patients, including risk factors and when to treat. This program will allow individuals who care for MS patients to optimize their treatment strategies, allowing for an improved quality of life in these individuals.
Target Audience
This activity is intended for neurologists and other healthcare professionals responsible for the diagnosis, treatment, or management of patients with multiple sclerosis.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Review multiple sclerosis subtypes, and discuss their appropriate symptomology and progressive characteristics.
- Examine the mechanisms of action of emerging therapies for the treatment of multiple sclerosis to ensure accurate treatment selection and initiation.
- Implement individualized treatment plans to effectively address patient-specific disease activity to reduce symptoms and improve quality of life for patients with multiple sclerosis
Faculty
| Fred Lublin, MD |
 | Suhayl S. Dhib-Jalbut, MD |
 | Patricia Coyle, MD
|
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflict of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
Name of Faculty or Presenter | Relationship Identified With: |
Fred Lublin, MD | Consultant/Advisor: Acorda Therapeutics, Inc.; Actelion Pharmaceuticals US, Inc; Akros Pharma, Inc; Bayer HealthCare Pharmaceuticals; BBB technologies; Bigoen Idec; Celgene Corporation; EMD Serono, Inc.; Forward Pharma; Genentech, Inc.; Genzyme Corporation; Hoffmann-La Roche Ltd; MedImmune, LLC; Novartis Pharmaceutical Corporation; Osmotica Pharmaceutical Corp; Questcor/Mallinckrodt; Receptos, Inc.; sanofi-aventis, U.S. LLC; Teva Neuroscience, Inc.; XenoPort, Inc. Grant/Research Support: Biogen Idec; Celgene; Genzyme Corporation; National Institutes of Health; National Multiple Sclerosis Society; Novartis Pharmaceuticals Corporation; Sanofi; Teva Neuroscience, Inc; Transparency Life Sciences Stock Ownership: Cognition Pharmaceuticals, Inc. Co-Chief Editor: Multiple Sclerosis and Related Diseases |
Suhayl S. Dhib-Jalbut, MD | Consultant/Advisor: Bristol-Myers Squibb Company; Genentech; Genzyme Corporation; Mallinckrodt Pharmaceuticals; EMD Serono, Inc.; Teva Neuroscience, Inc. Grant/Research Support: Biogen Idec; Teva Neuroscience, Inc. |
Patricia Coyle, MD | Consultant/Advisor: AbbVie, Inc.; Accordant; Acorda Therapeutics, Inc.; Bayer HealthCare Pharmaceuticals; Biogen Idec; Genzyme Corporation; sanofi-aventis U.S. LLC; Novartis Pharmaceuticals Corporation; EMD Serono, Inc.; Teva Neuroscience, Inc. Grant/Research Support: Actelion Pharmaceuticals US; Novartis Pharmaceuticals Corporation; Opexa Therapeutics |
Non-Faculty: Bernard M. Abrams, MD, Sandy Breslow, Alison Kemp, TImothy Hayes, MD, PhD, Kristen Scollon, Emma Gilmartin and Jaimie Kelly hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Financial Support
This CME activity is supported by an educational grant from Genentech, Inc.
Provider Information
Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.
Course Open Date: October 16, 2015 | Course Expiration Date: October 17, 2016
CME Credit (Physicians)
The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME Inquiries/Special Needs
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, AcademicCME, and Genentech, Inc. do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Available Credit
- 1.50 AMA PRA Category 1 Credit(s)™
- 1.50 Non-physician